Stockchase Opinions

Brianne Gardner Organon OGN-N DON'T BUY Dec 01, 2023

Recently on a downward trend. Fundamentally scores 3/10. Would not recommend buying. Price target falling. Has not been able to beat earnings. Better options available for investors. High debt levels not good for dividend outlook. 

$11.500

Stock price when the opinion was issued

Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

DON'T BUY

It has no growth.

BUY

Spun off from Merck two years, but has been sitting in the penalty box. Pays a 5.5% dividend at 5x earnings.